CTRI/2012/08/002940招募中不适用
A multicentre, randomized, open label, two-treatment, two-period, two sequence, single dose, crossover, bioequivalence study comparing Capecitabine Tablets USP 500 mg (Manufactured by: Hetero Labs Ltd, India) and the reference listed drug Xeloda® (Capecitabine) Tablets 500 mg (Distributed by Genentech USA, Inc., A Member of the Roche Group, South San Francisco, CA 94080) in locally advanced or Metastatic Breast Cancer or Colorectal Cancer adult subjects already receiving a stable twice-daily dosing regimen as prescribed by the reference product label under fed condition.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 64
- 试验地点
- 2
- 主要终点
- Establishing the bioequivalence between test and reference
研究概览
简要总结
This is a multicentre, randomized, open label, two-treatment, two-period, two sequence, single dose, crossover, study in locally advanced or metastatic Breast cancer or Colorectal cancer adult subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Not Applicable
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Established cases of advanced breast cancer or metastatic breast cancer or colo-rectal cancer who are already receiving a stable twice-daily dosing regimen in multiples of 500 mg tablet.
- •2.Life expectancy of at least 3 months 3.Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
排除标准
- •Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drug, or which may jeopardize the subject in case of participation in the study.
- •Positive alcohol or drug abuse test at baseline.
- •Diagnosis of AIDS, Hepatitis B, Hepatitis C infection defined as a positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody tests, respectively.
- •Have received any live or live attenuated vaccines within 2 months prior to randomization.
结局指标
主要结局
Establishing the bioequivalence between test and reference
时间窗: Day 1 and Day 2
次要结局
- AUClast AUCinf Cmax λz Tmax and T1/2 and other parameters as appropriate from plasma concentration time(Day 1 and Day 2)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Bioequivalence study ofDoxorubicin Hydrochloride (Pegylated liposomal concentrate for solution for infusion 20 mg/10mL (2 mg/ml) in advanced ovarian cancer.CTRI/2015/10/006241Dr Reddys Laboratories Limited50
招募中
不适用
Clinical trial to compare two drugs, Temodal and Temozolomide 250 mg capsules in cancer patientsCTRI/2011/12/002274Reliance Life Sciences Pvt Ltd24
尚未招募
不适用
A Clinical Trial of two drugs Paclitaxel (Test) and Abraxane® (Reference) to study the pharmacokinetics and safety in patients with metastatic breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapyCTRI/2025/05/086951Amneal EU Limited60
招募中
1 期
A Randomized, Open-Label, Multicenter, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 2mg/mL (50 mg/m dose)CTRI/2021/12/038914Alembic Pharmaceuticals Limited18
已完成
不适用
To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.CTRI/2012/07/002778Hetero Labs Ltd64